US 8,390,125

Application 13/052,258 · Granted Mar 5, 2013

Through-silicon via formed with a post passivation interconnect structure

Estimated expiration

April 5, 2030

3y 135d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Jan 8, 2010
+ 20 years
Jan 8, 2030
PTA +87d
Apr 5, 2030
No TD
—
Final
Apr 5, 2030

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
March 21, 2011
Earliest effective filing
January 8, 2010
Issue date
March 5, 2013
PTA
+87 days
Base expiry (before PTA)
January 8, 2030

January 8, 2010 + 20 years = January 8, 2030 + 87 PTA days = April 5, 2030

  • Continuation of application 12/684,859, filed Jan 8, 2010, issued as US 7,932,608
  • PRO61/154,979 — Provisional — not used for base term
  • PRO61/154,979 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/052,258 · US 8,390,125

PatentReply compiles the prosecution history behind US 8,390,125: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US8390125

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.